Preclinical investigations using [¹⁷⁷Lu]Lu-Ibu-DAB-PSMA toward its clinical translation for radioligand therapy of prostate cancer.

ABSTRACT: [¹⁷⁷Lu]Lu-Ibu-DAB-PSMA was previously characterized with moderate albumin-binding properties enabling high tumor accumulation but reasonably low retention in the blood. The aim of this study was to investigate [¹⁷⁷Lu]Lu-Ibu-DAB-PSMA in preclinical in vivo experiments and compare its therapeutic efficacy and potential undesired side effects with those of [¹⁷⁷Lu]Lu-PSMA-617 and the previously developed [¹⁷⁷Lu]Lu-PSMA-ALB-56. BALB/c nude mice without tumors were investigated on Day 10 and 28 after injection of 10 MBq radioligand. It was revealed that most plasma parameters were in the same range for all groups of mice and histopathological examinations of healthy tissue did not show any alternations in treated mice as compared to untreated controls.

SUBMITTER: Tschan VJ 

PROVIDER: S-EPMC9399046 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature